Lotte Biologics Plans Biopharmaceutical CDMO Plant in Songdo, South Korea

---

Researched by Industrial Info Resources (Sugar Land, Texas)--Lotte Biologics (Seoul, South Korea) plans to establish a mega contract development and manufacturing organization (CDMO) plant in Songdo, South Korea. The facility will produce antibody drug active pharmaceutical ingredients (APIs).

The overall project involves an investment of about US$3 billion to build three plants in Songdo by 2034. Each plant will have a production capacity of 120,000 liters of antibody drug APIs.

Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharma-Bio project and plant databases can click here for the related project reports and click here for the plant profile.

Lotte Biologics was established in 2022 as an affiliate of Lotte Group.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 Trillion (USD).